ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. (Q40397259)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 2005

Language	Label	Description	Also known as
English	ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.	scientific article published on August 2005

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

esophageal squamous cell carcinoma

1 reference

based on heuristic

inferred from title

Shunsuke Kagawa

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

author name string

Fuminori Teraishi

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Takanori Watanabe

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Yasuhisa Tango

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Takeshi Kawashima

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Tatsuo Umeoka

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Masahiko Nisizaki

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Noriaki Tanaka

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Toshiyoshi Fujiwara

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

579

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

4069-4075

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16023108%20AND%20SRC:MED&resulttype=core&format=json

31 December 2019

Esophageal carcinoma: current controversies

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

The epidermal growth factor receptor and its inhibition in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

The EGF receptor family as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Phase I studies of ZD1839 in patients with common solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Pro-survival function of Akt/protein kinase B in prostate cancer cells. Relationship with TRAIL resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Ectopic p21sdi1 gene transfer induces retinoic acid receptor beta expression and sensitizes human cancer cells to retinoid treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB.

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Regulation of Akt by EGF-R inhibitors, a possible mechanism of EGF-R inhibitor-enhanced TRAIL-induced apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2005.06.031

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40397259&oldid=1507526736"